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Abstract
Tetherin (BST-2/CD317) is an interferon-inducible antiviral protein that restricts the release of enveloped viruses from
infected cells. The HIV-1 accessory protein Vpu can efficiently antagonize this restriction. In this study, we analyzed
mutations of the transmembrane (TM) domain of Vpu, including deletions and substitutions, to delineate amino acids
important for HIV-1 viral particle release and in interactions with tetherin. The mutants had similar subcellular localization
patterns with that of wild-type Vpu and were functional with respect to CD4 downregulation. We showed that the
hydrophobic binding surface for tetherin lies in the core of the Vpu TM domain. Three consecutive hydrophobic isoleucine
residues in the middle region of the Vpu TM domain, I15, I16 and I17, were important for stabilizing the tetherin binding
interface and determining its sensitivity to tetherin. Changing the polarity of the amino acids at these positions resulted in
severe impairment of Vpu-induced tetherin targeting and antagonism. Taken together, these data reveal a model of specific
hydrophobic interactions between Vpu and tetherin, which can be potentially targeted in the development of novel anti-
HIV-1 drugs.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) interacts with a
series of host proteins that facilitate its replication in the cell and
exploits the host cell machinery to maximize viral particle
production [1]. There are multiple systems in host cells that
render them resistant to viral infection through the actions of
innate host cell restriction factors. Several host cell restriction
factors have been identified that target specific steps in the HIV-1
lifecycle, including APOBEC3G [2], TRIM5a [3] and the
recently identified tetherin protein (also known as BST-2,
CD317 or HM1.24) [4,5]. Viruses in turn have evolved to express
adaptor molecules that counteract important host cell restrictions,
such as illustrated by the Vif protein of HIV-1 which enhances the
proteasomal degradation of APOBEC3G [6] and the Vpu protein
which relieves the host restriction imposed by tetherin [4,5].
Tetherin has been identified as an interferon-inducible antiviral
host factor in HIV-1 infected cells. During the late phase of the
viral replication pathway, tetherin blocks the release of nascent
virions from HIV-1 infected cells at the plasma membrane and
prevents viral spread [4]. It is a 28- to 36-kDa type II integral
membrane glycoprotein with a unique topology which encodes a
short N-terminal cytoplasmic tail, a single transmembrane (TM)
spanning region, an extracellular coiled-coil domain and a
putative glycosyl-phosphatidlyinositol (GPI) anchor at its C-
terminus [7]. Tetherin is constitutively expressed in restrictive
human cell lines, including HeLa, H9, Jurkat, Molt4, primary T
lymphocytes and primary macrophages, while it is absent in cells
that are permissive for particle release, such as 293T, HOS and
HT1080 [4]. As expected from the formation of tethers to capture
enveloped viruses, tetherin has shown broad-spectrum inhibition
of the release of not only animal lentiviruses such as HIV-1 or SIV,
but also other viruses such as MLV, HTLV-1, Ebola, Lassa virus
and the Marburg virus [8,9,10]. As the name implies, tetherin is
presumed to provide a physical tether between the plasma
membrane and retained virions, and a recent study showed that
an artificial tetherin-like protein, assembled from fragments of
heterologous proteins, is able to mimic the biological activity of the
native tetherin [11].
HIV-1 Vpu is a 16-kDa type I integral membrane phospho-
protein [12,13]. It is an oligomeric protein with a short N-terminal
domain, an uncleaved leader sequence that also acts as a TM
domain and a longer cytoplasmic domain [14]. Two distinct
biological activities have been attributed to Vpu: enhancement of
viral particle release from the plasma membrane of infected cells
and the specific degradation of the HIV-1 receptor molecule CD4
in the endoplasmic reticulum (ER) [15]. These two biological
activities have been shown to operate via two distinct molecular
mechanisms and involve two separate structural domains: the N-
terminal TM domain for the enhancement of viral particle release
and the C-terminal cytoplasmic domain for surface downregula-
tion and proteasomal degradation of CD4 [16]. A conserved
casein kinase II phosphorylation motif in the Vpu C-terminal
cytoplasmic tail is responsible for binding to b-TrCP, which is
important in mediating CD4 degradation [17]. In particular, the
Vpu TM domain contains certain sequences important for the
enhanced release of virus particles [18], while recent data suggest
that the Vpu TM domain interacts with tetherin [19,20].
In this study, we performed a mutagenesis study of the HIV-1
NL4-3 Vpu TM domain in an attempt to better understand its role
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20890and key region in the process of HIV-1 viral particle release and in
Vpu-induced antagonism of tetherin. Most of the Vpu mutants
localized to subcellular compartments in a similar pattern to that
of wild-type Vpu and maintained the CD4 downregulation
function. The effects of these mutants on both exogenous and
endogenous tetherin were evaluated by different methods. Here,
we showed that the hydrophobic binding surface for tetherin lies in
the core of the Vpu TM domain. Most of the deletions in the
different regions of the N-terminus of Vpu resulted in profound
effects on its ability to antagonize tetherin, especially the three
consecutive hydrophobic isoleucine residues in the middle region.
Interestingly, two amino acid substitutions in the core region of the
Vpu TM domain, Vpu TM M3IV and Vpu TM M3IT, resulted
in distinct effects not only on tetherin targeting but also on Vpu-
mediated enhancement of viral particle release and tetherin
downregulation. The inability of the hydrophilic substitution
mutant to interact with tetherin demonstrated that the structural
stability of the binding surface is maintained by certain
hydrophobic amino acids in the helix. Taken together, these data
support a specific hydrophobic interaction model between the Vpu
TM domain and tetherin, and further demonstrate the feasibility
of blocking this interaction as a novel approach in anti-HIV-1
drug therapy.
Results
Construction and characterization of Vpu TM mutants
Previous studies have shown that the Vpu TM domain of HIV-
1 is critical for virus release and that it regulates Vpu activity in the
release of virus-like particles (VLPs) from the plasma membrane
[18]. However, the mechanisms by which the Vpu protein
enhances the release of virus particles were not clearly understood
before the identification of its restriction factor tetherin. Here, we
focused on analyzing conserved amino acids within the native Vpu
TM domain to determine their role and relative importance in
HIV-1 viral particle release and the antagonistic activities against
tetherin. A series of mutations were introduced into the
hydrophobic N-terminus of HIV-1 NL4-3 Vpu by PCR-directed
mutagenesis, and the sequences of the mutants analyzed in this
study are shown in Fig. 1A. Several deletion mutants were initially
constructed, including two constructs (Vpu D2-11 and Vpu D12-
21), each with a large deletion of ten amino acids in the Vpu TM
domain, and three mutants with shorter deletions of two (Vpu TM
ND2I, Vpu TM CD2I) or three (Vpu TM MD3I) conserved
isoleucines in the N-terminal, middle, or C-terminal parts of Vpu
TM domain. Our preliminary results based on these deletion
mutants revealed that mutations in the conserved Ile motif of Vpu
TM MD3I severely reduced its activity against tetherin. To
address whether the amino acid specificity or the polarity is the
more important determinant in Vpu sensitivity to tetherin, the
mutants Vpu TM M3IV and Vpu TM M3IT were generated by
introducing substitutions of the hydrophobic Ile residues (polarity
value=5.200) within the middle portion of the TM domain, where
Ile15, Ile16 and Ile17 were replaced by Val (hydrophobic, polarity
value=5.900) or Thr (hydrophilic, polarity value=8.600) [21].
Furthermore, a Vpu protein with both serine residues of the two
casein kinase II sites changed to alanine residues (Vpu S52/56A)
was used as a negative control [16]. All of the Vpu variants were
expressed at approximately the same levels in HeLa and 293T
cells (data not shown). Interestingly, the Vpu D12-21 truncated
protein was obviously smaller than Vpu D2-11 in the SDS PAGE
analysis. We hypothesized that the deletion in the Vpu D12-21
mutant may have generated a secretory leader peptide which was
cleaved during expression, resulting in a Vpu protein devoid of
most of the transmembrane domain, similar to the generation of a
tetherin delTM mutant recently reported by another group [11].
Vpu is an oligomeric type I integral membrane protein that
forms high-molecular-weight complexes in vivo and in vitro [14].
The oligomerization of this protein is mainly induced by its TM
domain. It must remain a stable helix in this environment and
oligomerize to normally interact with most other related host
proteins. To verify this basic characteristic in the Vpu TM
mutants, we analyzed them by native and denaturing gel
electrophoresis. 293T cells transfected with Vpu variants were
divided into two groups and each lysed in either RIPA buffer
(denaturing) or co-immunoprecipitation (co-IP) lysis buffer (na-
tive). The cell lysates were then mixed with either SDS sample
buffer or native sample buffer. The denatured samples were boiled
and separated on a 12.5% SDS gel at room temperature, while the
native samples remained unboiled and were separated on a 12.5%
native gel in a cold room (4uC). The gels were subsequently
analyzed by Western blot using an anti-myc antibody. As shown in
Fig. 1B (upper panel), the native wild-type Vpu protein appeared
as one major fragment with a molecular weight slightly larger than
the 80 kDa reported earlier in the literature [14]. We believe that
this difference in molecular weights may have been due to the
additional myc tag. Among the Vpu mutants, the two truncated
mutants Vpu D2-11 and Vpu D12-21 each appeared as a blurred
band, the lower ends of which were similar in size to the
corresponding bands on the denaturing gel. However, the other
deletion and substitution Vpu TM mutants did not show obvious
differences with the wild-type Vpu and Vpu S52/56A.
Although Vpu appears to act on a host protein that exerts its
inhibitory activity on HIV-1 particle release at the cell surface, the
most-studied subtype B Vpu was found to localize predominantly
in the trans-Golgi network (TGN) and to a lesser extent in the ER
and the recycling endosomes [22]. In contrast to the prototypical
subtype B Vpu, however, the subtype C Vpu protein was found to
localize both at the plasma membrane and in the Golgi complex
[23]. The domain responsible for this TGN localization was later
mapped to the Vpu TM proximal region, which contains two
overlapping putative sorting signals (tyrosine-based YXXW and di-
leucine based (D/E)XXXL(L/I)) [24]. As it is another fundamen-
tal characteristic which may affect the interaction with host
proteins, the subcellular localization of the Vpu mutants were
examined using immunofluorescence microscopy. Subconfluent
monolayers of HeLa cells were transfected with empty vector or
Vpu variant expression plasmids. Intracellular localization was
evaluated by an indirect immunofluorescence technique using the
anti-myc antibody to label Vpu and an anti-TGN46 antibody to
stain the relevant subcellular marker as described in Materials and
Methods. As shown in Fig. 1C, wild-type Vpu was mostly
associated with the TGN marker and appeared as many small
punctate structures which suggested that it mainly accumulated in
the endosomes. Meanwhile, other Vpu mutants except for two
were predominantly expressed with this similar profile. Although
still partially associated with the TGN marker, the distribution
pattern of Vpu D2-11 was moderately dispersed, while that of Vpu
D12-21 was extensively diffuse. Except for these two truncated
Vpu proteins, the patterns of the other Vpu TM mutants appeared
similar to that of the wild-type Vpu and Vpu S52/56A.
From the results above, we could simply reason that the five
short point mutations (Vpu TM ND2I, Vpu TM MD3I, Vpu TM
CD2I, Vpu TM M3IV and Vpu TM M3IT) did not grossly impact
the oligomerization nor the subcellular distribution of Vpu.
Meanwhile, Vpu D2-11 and Vpu D12-21 failed to oligomerize,
and their subcellular localizations also changed, suggesting that
these truncations resulted in major damage to the TM domain. To
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membrane Vpu proteins although they still retain several
hydrophobic amino acids in the N-terminus and the Vpu C-
terminal tail.
Defective Vpu TM mutants fail to enhance HIV-1 virus
release
Vpu is required for efficient HIV-1 particle release in certain
human cells [25], and HeLa cells are a prototypic example of cells
that exhibit this requirement [26]. Recent observations have
shown that endogenous tetherin is constitutively expressed in
HeLa cells [4]. To determine the impact of the alterations
introduced into the TM domain of Vpu on its ability to enhance
virus particle release, we examined the effect of these mutants on
the Vpu-mediated recovery of HIV-1 Vpu defective particle
release from HeLa cells. HeLa cells were co-transfected with
pNL4-3 DVpu proviral plasmids and empty vector or Vpu
variants expression plasmids. Transfection of the pNL4-3 wild-
type vector along with empty vector was used as a positive control.
After 48 h of incubation, HIV-1 producing cells and supernatants
were harvested. Vpu was detected in the cell lysates by
immunoblotting, and Pr55Gag was also detected as a transfection
efficiency control. Viral particles were further isolated from the
supernatants by ultracentrifugation as described in Materials and
Methods. The release of viral particles was first evaluated by
immunoblotting with anti-p24 capsid antibodies. As shown in
Fig. 2A, the NL4-3 DVpu proviral clone displayed severe defects in
virion p24 release compared with the NL4-3 WT clone (Fig. 2A,
lanes 1 and 2), while viral p24 was recovered almost at the same
level as the NL4-3 WT clone in the presence of Vpu WT (Fig. 2A,
lane 3). The Vpu S52/56A retained ,40% of the ability of the
wild-type Vpu to enhance virus release (Fig. 2A, lane 4). By
contrast, the two Vpu TM truncation mutants, VpuD2-11 and
VpuD12-21, both exhibited significant attenuation (,90% de-
crease) in the efficiency of viral particle release compared with that
of the Vpu WT (Fig. 2A, lanes 5 and 6). Among the three short
Figure 1. Schematic representation and basic characteristics of Vpu TM mutants. (A) Deletion and substitution mutagenesis of the Vpu TM
domain. The numbering of amino acid residues used is based on the original Vpu sequence of NL4-3. The deleted amino acids are indicated by the
dashes, and the substituted amino acids within the TM region are represented in bold. (B) PAGE analysis of Vpu TM mutants under native and
denaturing conditions. Lysates from the Vpu variants transfected 293T cells were mixed with SDS sample buffer or native sample buffer and
subjected to standard SDS-PAGE or native PAGE, respectively. The gels were transferred to a nitrocellulose membrane and further analyzed by
immunoblotting using a mouse anti-myc antibody to detect myc-tagged Vpu protein. The upper panel shows the native condition and the lower
panel shows denaturing condition. (C) Subcellular localization of Vpu TM mutants. HeLa cells transfected with Vpu variant expression plasmids were
fixed and double stained with a mouse anti-myc antibody (green) and a rabbit anti-TGN46 antibody (red). Images were taken under a fluorescence
microscope. At least 30 independent cells were examined in each sample, and the most representative cells are shown.
doi:10.1371/journal.pone.0020890.g001
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ability to enhance virus release compared to the wild-type (Fig. 2A,
lane 7). Conversely, cells that expressed either the Vpu TM MD3I
or Vpu TM CD2I mutant showed an impairment of ,90% in
capsid protein release (Fig. 2A, lanes 8 and 11). Importantly, cells
that expressed Vpu TM M3IV released 3-fold more capsid
proteins than its hydrophilic counterpart Vpu TM M3IT. This
substitution mutant Vpu TM M3IV was found to recover virus
release nearly as efficiently as the Vpu WT (,75%), which
suggested that the amino acid polarity at this mutation site was
very important in determining the ability of Vpu to enhance virus
release. To confirm these observations, we also evaluated the
release of viral particles in parallel by a more sensitive method, a
relative infectivity assay scored by titration of the supernatant on
MAGI-CCR5 indicator cells. The amount of virus released in the
supernatant was determined by comparing the ratio of relative
infectious particles released in the presence of the indicated Vpu
mutant to that of NL4-3 WT. As shown in Fig. 2B, the relative
infectivity levels corresponded with the viral capsid protein output
detected in the supernatant. From these results, we concluded that
certain deletions and substitutions introduced in the TM domain
of Vpu impaired its ability to optimally enhance viral particle
release.
Contribution of degradation and surface downregulation
in Vpu-induced impairment of tetherin function
Although tetherin has been studied for over 3 years in the HIV-
1 field, the mechanism by which Vpu antagonizes it is still not
clearly defined. The explanations mainly include degradation, cell
surface downregulation, and interrupting recycling of the tetherin
protein. To further characterize the Vpu TM mutants using more
relevant approaches, we therefore attempted to delineate these
mechanisms as described below.
In order to investigate the relative contributions of degradation
and surface downregulation to the Vpu-mediated antagonism of
tetherin, we carried out the following experiments. First, we
expressed HA-tetherin in Vpu-permissive 293T cells, which do not
express endogenous tetherin. By measuring released capsid
proteins (Fig. 3A) or by titrating the viral output (Fig. 3B), the
Vpu defective HIV-1 viral particles were found to exhibit
significant impairment in their ability to release from cells that
express HA-tetherin, while the wild-type virus was able to
overcome this inhibition. Remarkably, approximately 50% of
tetherin was degraded in the presence of HIV-1 which expressed
proviral Vpu. Subsequently, to delineate the correlation between
Vpu-mediated tetherin degradation and dysfunction, we trans-
fected 293T cells in the same conditions as that shown in the right
panel of Fig. 3A along with increasing Vpu/tetherin ratios of
expression plasmids. The results showed that the tetherin
degradation was very apparent, especially in the presence of high
Vpu levels, suggesting that this Vpu-mediated degradation of
tetherin occurred in a dose-dependent manner (Fig. 3C). Increas-
ing the dose of Vpu accordingly rescued the viral particle release,
which paralleled the decrease in tetherin antiviral activity.
However, only traces of Vpu were sufficient to efficiently suppress
the tetherin antiviral function (Fig. 3D). Similar experiments were
also carried out in HeLa cells, which express endogenous tetherin.
HIV-1 WT was used as the positive control and pEGFP-N3 was
used for confirming transfection efficiency in the FACS analysis.
As shown in Fig. 3E, increasing the dose of Vpu rescued the viral
particle release, and the Vpu amount seemed to correlate with the
released p24 levels. By using Vpu anti-serum, Vpu-cmyc and viral
Vpu could both be detected. The levels of cell surface tetherin
were evaluated by flow cytometry, with cells only transfected with
pEGFP-N3 and empty vector as negative controls (Fig. 3F).
Samples were gated on EGFP+ cells, and the surface tetherin
levels were determined and presented in the histograms with
median values. As shown in Fig. 3F, HIV-1 WT which expressed
viral Vpu efficiently downregulated surface tetherin, while Vpu
deficient HIV-1 lost this activity. However, with increasing
amounts of exogenous Vpu, the surface tetherin levels decreased
in a dose-dependent manner. The amounts of Vpu, surface
tetherin and capsid release levels are plotted in a line graph in
Fig. 3G to better illustrate the relationships between these factors.
Taken together, these results demonstrated that surface
downregulation plays an important role in the mechanism by
which Vpu antagonizes tetherin. However, a poor correlation was
identified between the Vpu-mediated tetherin degradation and
loss of its function. Although total cellular degradation has been
reported to be a redundant mechanism for the Vpu-induced
tetherin antagonism in the most recent literature reports, it is
indeed an important consequence of Vpu/tetherin interaction
which should also be considered. To some extent, it would be of
Figure 2. Defective Vpu TM mutants fail to enhance HIV-1 virus
release. (A) VR1012 control vector or VR1012 encoding Vpu TM
variants (500 ng each) was co-transfected with 1 mg proviral plasmids of
pNL4-3 WT or pNL4-3DVpu in HeLa cells. At 48 h post-transfection, the
cultured supernatants were ultracentrifuged to concentrate the virus
particles. The virions and the cell lysates were analyzed by immuno-
blotting using an anti-p24 antibody to detect virion p24 capsid and
intracellular Pr55Gag proteins, anti-myc antibody to detect myc-tagged
Vpu and an antibody against tubulin to assess sample loading. The viral
Pr55Gag protein was examined to exclude variations of transfection
efficiency. (B) The relative infectivities of virus released from the cells
transfected in (A) were assayed by infecting MAGI cells with equal
volumes of supernatant samples. The cells were then fixed and stained
for b-galactosidase activity. Virus release of NL4-3 WT was set to 100%.
The graph was generated from two independent experiments each
performed in duplicate.
doi:10.1371/journal.pone.0020890.g002
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exogenous tetherin protein.
Effects of Vpu TM mutations on Vpu-mediated
degradation and surface down-regulation of tetherin
To analyze the contribution of the Vpu TM domain to the
degradation of tetherin, we co-expressed HA-tetherin and Vpu
variants at a fixed molar ratio that led to significant tetherin
depletion, as observed in Fig. 3C. 293T cells were co-transfected
with vectors expressing either the Vpu wild-type or mutated Vpu
proteins and HA-tetherin. At 48 h, the cells were lysed and Vpu
and tetherin were analyzed by immunoblotting. The results shown
in Fig. 4A indicated that cells expressing Vpu wild-type induced a
notable level of tetherin degradation, while Vpu S52/56A still
retained half of the ability to induce tetherin degradation
compared to the wild-type (Fig. 4A, lanes 2 and 3). Strikingly,
the two Vpu TM truncation mutants, Vpu D2-11 and Vpu D12-
21, exhibited strong functional defects and completely failed to
mediate tetherin degradation (Fig. 4A, lanes 4 and 5). As expected,
the three short deletion mutants partially affected Vpu-mediated
tetherin degradation. The Vpu TM ND2I mutant still maintained
,50% of the ability to degrade tetherin compared to the wild-
type; however, the other two mutants Vpu TM MD3I and Vpu
TM CD2I showed an extensive loss of this function. Interestingly,
a couple of amino acid substitutions again exhibited distinct effects
on tetherin degradation. Vpu TM M3IV was found to degrade
tetherin nearly as efficiently as the Vpu WT, while the Vpu TM
M3IT mutant exhibited a level of function fundamentally as
defective as its corresponding deletion mutant Vpu TM MD3I.
To further test the ability of the Vpu variants to induce surface
downregulation of endogenous tetherin, the tetherin positive HeLa
cells were co-transfected with the Vpu variants and pEGFP-N3 as
a marker. Cell surface tetherin was stained with anti-tetherin
monoclonal antibodies and analyzed by flow cytometry. The
samples were gated on EGFP+ cells, and the surface tetherin levels
are shown in histograms with median values. As shown in Fig. 4C,
cell surface tetherin was efficiently downregulated in cells which
expressed wild-type Vpu, while the downregulation was weak in
cells which expressed Vpu S52,56A. Both Vpu D2-11 and Vpu
D12-21 failed to downregulate tetherin completely. The ability of
Figure 3. Roles of degradation and surface downregulation in Vpu-induced tetherin dysfunction. (A) 293T cells were co-transfected with
1 mg pNL4-3 WT or pNL4-3DVpu and 50 ng HA-tetherin or empty vector. At 48 h, the cells were examined for tetherin expression, and the pelleted
virions were analyzed for p24 content. Pr55Gag was examined to exclude variations in transfection efficiencies. Tubulin was detected as a loading
control. (B) The relative infectivity of virus released in (A) was assayed by infecting MAGI cells. Virus release of NL4-3 WT in the absence of tetherin was
set to 100%. (C) 293T cells were co-transfected with 1 mg pNL4-3DVpu, 50 ng HA-tetherin and increasing doses of Vpu. HA-tetherin and Vpu-cmyc
were detected in the cells. (D) The cellular tetherin levels and virus released were plotted in a line graph. The tetherin level in the absence of Vpu was
set to 100%. Viral output was scored by titration of the supernatants on MAGI cells, and that without tetherin was set to 100%. (E) HeLa cells were co-
transfected with 1 mg pNL4-3DVpu or WT, along with 500 ng pEGFP-N3, and increasing doses of Vpu. Vpu was detected in the cells with Vpu
antiserum, and the pelleted virions were analyzed for p24 content. (F) Surface tetherin of cells in (E) were stained with tetherin antibodies and
analyzed by flow cytometry. Cells only transfected pEGFP-N3 was used as a negative control. The samples were gated on EGFP+ cells, and surface
tetherin levels are shown in histograms with median values at the top right corner. (G) The levels of surface tetherin and virus released are shown in a
line graph. The tetherin level in the negative control was set to 100%. Viral output was scored by titration of the supernatants on MAGI cells, and that
of NL4-3 WT was set to 100%. All values are representative of three independent experiments.
doi:10.1371/journal.pone.0020890.g003
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and that of Vpu TM CD2I was also defective to a lesser extent.
Meanwhile, Vpu TM ND2I still retained a partial ability to
downregulate tetherin. Remarkably, the substitution mutant Vpu
TM M3IV could strongly downregulate tetherin, while its
hydrophilic partner Vpu TM M3IT only showed slightly
moderate effects in tetherin downregulation. Although the Vpu-
induced tetherin antagonism was previously shown to be
dependent on surface downregulation of the target protein, here
it appeared that Vpu-induced cell surface tetherin downregulation
assay resulted in similar profiles with the transient degradation
assays. To conclude simply, the Vpu TM mutations impacted the
Vpu-mediated tetherin degradation and cell surface downregula-
tion to different extents, which essentially correlated with their
capabilities to enhance virus release.
Defective Vpu TM mutants potently block Vpu/tetherin
interaction
The Vpu-CD4 TM hybrid protein is known not to enhance the
release of virions [18], implying that the TM domain of Vpu is
critical for the interaction with tetherin. Recent studies have
shown the existence of physical interactions between Vpu and
tetherin [19,27]. In order to explore the possible mechanisms
involved in the enhancement of viral release and tetherin
downregulation by Vpu, we tested the ability of the Vpu TM
mutants to bind tetherin by co-IP. 293T cells were co-transfected
with HA-tetherin in the presence or absence of Vpu variants. The
Vpu mutated proteins were immunoprecipitated with anti-myc
antibody, and the cell lysates and precipitates were analyzed by
immunoblotting to detect the presence of tetherin. The results
showed that tetherin was specifically co-precipitated with Vpu
WT, and no tetherin was detected in the control precipitates in the
absence of Vpu (Fig. 5, lanes 1 and 2). As expected, Vpu S52/56A
also efficiently co-immunoprecipitated with tetherin. Notably, the
truncated Vpu TM mutants, Vpu D2-11 and Vpu D12-21, along
with the Vpu TM MD3I mutant with a deletion introduced in the
central part of the TM domain, completely lost the ability to
interact with tetherin (Fig. 5, lanes 4, 5 and 7). Densitometric
measurements of the blot in Fig. 5 show that compared with the
level of tetherin bound to Vpu WT (100%), ,50% bound to Vpu
TM ND2I, and ,25% bound to Vpu TM CD2I. Remarkably,
substitution mutants Vpu TM M3IV and Vpu TM M3IT
Figure 4. Effects of Vpu TM mutations on Vpu-mediated degradation and surface downregulation of tetherin. (A) 293T cells were co-
transfected with 100 ng HA-tetherin expression plasmid along with 200 ng VR1012 control vector or VR1012 encoding Vpu TM variants at a 2:1 molar
ratio. At 48 h post-transfection, the cells were harvested for immunoblotting analysis. Tetherin and Vpu were detected with anti-HA and anti-myc
antibody, respectively. Tubulin was detected as a loading control. (B) Tetherin levels were measured using Bandscan software and normalized by
tubulin levels. Percentages of degraded tetherin were calculated by subtracting the densitometric intensity values of the indicated Vpu WT or mutant
bands from that of the mock band to represent the different abilities of Vpu variants to mediate tetherin degradation. Values are representative of
three independent experiments. (C) HeLa cells were co-transfected with 500 ng pEGFP-N3 along with 500 ng VR1012 control vector or VR1012
encoding Vpu TM variants. Cell surface tetherin was stained with BST-2 antibodies, followed by Alexa 633 goat anti-mouse IgG and analyzed by flow
cytometry. Samples were gated on EGFP+ cells, and the surface tetherin levels are shown in the histograms with median values at the top right
corner.
doi:10.1371/journal.pone.0020890.g004
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interact with tetherin (Fig. 5, lanes 8 and 9). The Vpu TM M3IV
mutant, which potently down-regulated and degraded tetherin,
retained .80% of its ability to interact with tetherin although less
efficiently than Vpu WT. On the other hand, the Vpu TM M3IT
mutant which was partially impaired in the ability to downregulate
and degrade tetherin, retained only ,10% of its tetherin-binding
ability. Although this result may not be surprising, the inability of
this substitution mutant to interact with tetherin demonstrated that
certain hydrophobic amino acids in the Vpu TM domain may
play a key role in stabilizing its tetherin binding interface and
determining its sensitivity to tetherin.
Effects of Vpu TM mutations on Vpu-mediated
degradation and surface down-regulation of CD4
In Vpu-expressing cells, the surface CD4 receptor is downreg-
ulated and rapidly degraded in the ER [28]. The cytoplasmic
domains of Vpu and CD4 are critical for Vpu-mediated down-
modulation of CD4 [29,30], although the Vpu TM domain has
been implicated during this process [31]. Therefore, we also tested
whether our Vpu mutants had decreased abilities to downregulate
and degrade CD4. For the degradation assay, 293T cells were co-
transfected with CD4-HA in the presence or absence of the Vpu
variants. After 48 h, the cells were collected and analyzed by
immunoblotting for CD4 levels. As expected, the wild-type Vpu
caused notable degradation of CD4, while the Vpu S52/56A
mutant failed to completely reduce CD4 (Fig. 6A, lanes 2 and 3).
The mutants Vpu TM ND2I, MD3I, M3IV and M3IT retained
the ability to degrade CD4 (Fig. 6A, lanes 6, 7, 8, 9), indicating
that Vpu TM MD3I and M3IT are specifically defective in their
interactions with tetherin. The fact that Vpu TM CD2I showed
only a moderate reduction in its ability to degrade CD4 is also
reasonable since the mutation site may be close to the cytoplasmic
region (Fig. 6A, lane 10). Vpu D2-11 led to a moderate reduction
of CD4, while that of Vpu D12-21, whose TM domain was nearly
entirely deleted as described above, was completely blocked
(Fig. 6A, lanes 4 and 5). The immunoblot of CD4 levels was also
scanned and graphed to quantitate the different abilities of Vpu
variants to mediate CD4 degradation (Fig. 6B).
To examine the ability of Vpu variants to downregulate surface
endogenous CD4, HeLa CD4 cells were transfected with the Vpu
variants and pEGFP-N3 as a marker. Cell surface CD4 was
stained with CD4 antibodies and analyzed by flow cytometry.
Samples were gated on EGFP+ cells, and the surface CD4 levels
are shown in histograms with median values (Fig. 6C). Cell surface
CD4 was significantly reduced in the presence of wild-type Vpu,
while it was only slightly reduced by the expression of Vpu S52/
56A. The abilities of most of the Vpu TM mutants to
downregulate CD4 were not drastically affected, except for the
truncations Vpu D2-11, Vpu D12-21, and Vpu TM CD2I whose
mutation is close to the cytoplasmic region. The results of this flow
cytometry analysis appeared to be consistent with the transient
CD4 degradation assays. Again, Vpu had similar effects on both
endogenous and exogenous CD4 proteins. However, unlike its
activity against tetherin, the effects of Vpu on CD4 degradation
here seemed more striking than on surface CD4 downregulation.
Discussion
In this study, we explored the role of the HIV-1 Vpu TM
domain in Vpu-mediated HIV-1 viral particle release and tetherin
antagonism. We performed a mutational analysis of the Vpu TM
domain in an attempt to better understand the structural
requirements of this domain with respect to its biological function.
On the whole, the results from our current study demonstrated
that the hydrophobic binding surface for tetherin lies in the core of
the Vpu TM domain. The structural stability of the binding
surface is maintained by the hydrophobic amino acids in the helix,
and a deletion or polarity change in this particular region of Vpu
could lead to severe impairment of its tetherin antagonistic
function while neither affecting its subcellular localization nor anti-
CD4 function.
Research on Vpu has lasted for over 20 years since its
identification [12,13], and a large number of studies have been
focused on explaining the Vpu-mediated enhancement of HIV-1
virion release. Although most earlier attempts to map the Vpu
domains necessary for enhanced virus release were inconclusive, it
is generally accepted that the HIV-1 Vpu TM domain is capable
of forming cation-selective ion channels presumably at the plasma
membrane [32,33]. Accordingly, Paul and colleagues introduced
certain mutations into the TM domain of Vpu which caused great
defects in the ability of the protein to enhance the release of virus-
like Gag particles [18]. It was presumed that these mutations
perhaps disrupted some of the structural elements that constitute
active ion channels in the membrane. In addition, many other
models have been proposed over the years to delineate the
mechanism of Vpu-mediated enhancement of virus release.
However, the observation that fusions between Vpu-permissive
and Vpu-non-permissive cells exhibit the non-permissive pheno-
type predicted that Vpu counteracts a host cell restriction factor
for HIV-1 particle production [34]. Two groups later indepen-
dently identified tetherin as the protein that specifically inhibits
virion release and is counteracted by Vpu [4,5]. Undoubtedly, the
Figure 5. Defective Vpu TM mutants potently block the
physical interaction between Vpu and tetherin. 293T cells were
co-transfected with 1 mg VR1012 control vector or VR1012 encoding
Vpu TM variants together with 2 mg HA-tetherin expression vector at a
1:2 molar ratio to minimize the Vpu-mediated tetherin degradation.
Cells were harvested 48 h later and subjected to immunoprecipitation
using the anti-myc antibody and protein G agarose beads. Cell lysates
or co-precipitated proteins were analyzed by immunoblotting to detect
HA-tetherin and Vpu-cmyc. Equal loading was controlled by monitoring
tubulin. The level of tetherin in each sample was quantified by
densitometry, normalized by tubulin levels and shown beside the
tetherin blot. The value obtained with the positive control Vpu WT was
defined as 100%.
doi:10.1371/journal.pone.0020890.g005
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tal new knowledge in the field, which has, at least temporarily,
replaced earlier Vpu functional models and shifted the general
focus onto the functional impairment of tetherin induced by Vpu.
Vpu localizes to the TGN and endosomal compartments, which
has been shown to be necessary for its counteraction against
tetherin [24]. In addition, the recycling of tetherin between the cell
surface and perinuclear region is also dependent on TGN [7,35].
Since the long truncations in Vpu D2-11 and Vpu D12-21 may
have destroyed the stable helix of the TM domain in the
hydrophobic environment, the gross subcellular mislocation could
have resulted in the defects in tetherin antagonism. However, the
diffuse localization of Vpu D2-11 and Vpu D12-21 (Fig. 1C) may
because the protein is mainly in the ER (note their visible nuclear
membrane). This correlates with the evidence from the native gel
that suggests gross changes in Vpu oligomer structure (Fig. 1B).
These observations are consistent with a quite recent study which
reported that Vpu-A18H mutant was confined to an ER-like
distribution, resulting in impaired downregulation of tetherin and
reduced virion release [36]. Meanwhile, the other mutants that
possessed small alterations in the TM domain were still able to
localize in TGN (Fig. 1C). A short deletion may tighten a certain
part of the transmembrane helix, while a substitution of a residue
that alters the polarity may affect the electric charge distribution in
a certain region. However, the observation that some of these
mutations extensively impaired the tetherin antagonism of Vpu
suggested that Vpu localization to the TGN and Vpu-induced
counteraction against tetherin are two independent events.
Our observations of the effect of Vpu TM mutants on the
enhancement of virion particle release (Fig. 2A, 2B) were
essentially consistent with a previous report [18]. The Vpu TM
N-terminal, middle and C-terminal deletion mutants showed
moderate to profound effects in their ability to enhance viral
particle release. In particular, the impairment of a Vpu TM
middle deletion mutant (TM MD3I) was quite severe and resulted
in nearly complete loss of function. These results strongly
suggested that the Vpu TM domain contains determinants
responsible for Vpu-mediated enhancement of viral particle
release. Interestingly, the results with the mutants containing
substitutions of consecutive isoleucine residues in the Vpu TM
middle region hinted that the polarity of certain amino acids in this
domain may greatly influence the ability of Vpu to enhance viral
particle release. Although the HIV-1 Vpu contains a 27 amino
acid TM domain (NL4-3 strain) at the N-terminus, it is predicted
Figure 6. Effects of Vpu TM mutations on Vpu-mediated degradation and surface downregulation of CD4. (A) 293T cells were co-
transfected with 100 ng CD4-HA expression plasmid along with 200 ng VR1012 control vector or VR1012 encoding Vpu TM variants. At 48 h post-
transfection, the cells were harvested for immunoblotting analysis. CD4 and Vpu were detected with anti-HA and anti-myc antibodies, respectively.
Tubulin was detected as a loading control. (B) CD4 levels were measured using Bandscan software and normalized by tubulin levels. Percentages of
degraded CD4 were calculated by subtracting the densitometric intensity values of the indicated Vpu WT or mutant bands from that of the mock
band to represent the different abilities of Vpu variants to mediate CD4 degradation. Results shown are the average of two independent experiments.
(C) HeLa CD4 cells were co-transfected with 500 ng pEGFP-N3 along with 500 ng VR1012 control vector or VR1012 encoding Vpu TM variants. Cell
surface CD4 was stained with CD4 antibodies followed by Alexa 633 goat anti-mouse IgG and analyzed by flow cytometry. Samples were gated on
EGFP+ cells, and the surface CD4 levels are shown in the histograms with median values at the top right corner.
doi:10.1371/journal.pone.0020890.g006
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observation that the Vpu TM N-terminal deletion mutants (TM
ND2I) showed weaker impairment of tetherin antagonism than
TM MD3I and TM CD2I provided evidence demonstrating that a
short N-terminal tail of the TM domain may be exposed outside
the phospholipid bilayers.
The precise mechanism of Vpu counteraction against tetherin
to stimulate virus release is not clearly defined at present. Until
now, the explanations mainly include degradation, cell surface
downregulation, and interrupting recycling of the tetherin protein.
Initial studies were able to measure a reduction in total cellular
tetherin levels resulting from Vpu expression, and proposed a
degradation-dependent mechanism [27,37,38,39], which is similar
to that used by HIV-1 Vif to overcome the host antiviral factor
APOBEC3G [2,6]. Notably, most of the tetherin investigated in
these reports were exogenous proteins generated from transient
transfection. Many studies also used flow cytometry based analyses
and clearly indicated that the levels of endogenous tetherin at the
cell surface of HeLa cells are markedly diminished in the presence
of Vpu [5,38,39,40,41]. However, by contrast, more recent studies
support a degradation-independent mechanism. Importantly,
Miyagi and colleagues carried out extensive experiments in
HIV-1 infected T cells and suggested that Vpu could relieve the
blockade of viral release in certain cells lines in the absence of
tetherin surface downregulation or depletion [40]. In addition,
another group also provided evidence that Vpu can efficiently
antagonize virion tethering in the absence of CD317 degradation
[42]. In a very recent study, Andrew and colleagues analyzed the
effects of Vpu on tetherin by performing a series of kinetic studies
and indicated that surface downregulation of tetherin is caused by
interference with the resupply of newly synthesized tetherin from
within the cell [43], which provided a new explanation for Vpu-
mediated tetherin conteraction. Finally, Douglas et al. has
illustrated that experiments carried out in different cell types,
with different tetherin sources and Vpu sources expressed at
different levels, may lead to the distinct conclusions [44].
Naturally, the most reliable assay to delineate the precise
antagonizing mechanism may be to investigate the interaction
between viral Vpu and endogenous tetherin of host cells upon
HIV-1 virus infection.
Our experiments using increasing Vpu doses were predomi-
nantly aimed at determining the reliable assay to test the effects
of Vpu mutants and the contribution of degradation and cell
surface downregulation in Vpu-induced impairment of tetherin
function. The Vpu of HIV-1 wild-type provirus could diminish
the total cellular levels of tetherin and inhibited its function
(Fig. 3A, 3B), suggesting that proviral Vpu induces, at least to
some extent, the degradation of exogenous tetherin. In 293T
cells, Vpu provided in trans could rescue HIV-1 DVpu release
and induce the degradation of tetherin in a dose-dependent
manner. However, degradation of a low fraction of the total
tetherin was sufficient to neutralize tetherin-mediated virion
release inhibition (Fig. 3C). Meanwhile, in tetherin positive
HeLa cells, increasing the dose of Vpu also rescued HIV-1 DVpu
release and simultaneously induced the downregulation of cell
surface tetherin (Fig. 3E, 3F). The negative correlations of cell
surface tetherin to released virus from the HeLa cells are well-
illustrated when plotted in the line graphs (Fig. 3D, 3G).
Comparison of these graphs suggest that tetherin cell surface
downregulation is a more significant biological consequence of
and perhaps more correlative with Vpu function than tetherin
degradation. Although these two assays when used to evaluate
the function of Vpu mutants provided similar profiles on both
endogenous and exogenous tetherin proteins (Fig. 4A, 4B, 4C),
their effects on tetherin surface downregulation seemed more
striking than on tetherin degradation.
There is currently controversy as to whether the b-TrCP
mechanistic pathway is involved in Vpu-induced tetherin
antagonism. Vpu is capable of diminishing the total amounts of
tetherin in cells, and this activity relies on the recruitment of b-
TrCP [27,38,39,41]. The major Vpu-responsive site has now been
mapped to the tetherin STS motif (positions 3 to 5) that undergoes
Vpu/b-TrCP-dependent ubiquitination [45]. Nevertheless,
whether Vpu antagonizes tetherin antiviral activity in a b-TrCP-
dependent manner is still under debate. Here, our data
demonstrated that the Vpu S52/56A mutant which was impaired
for b-TrCP recruitment could perfectly interact with tetherin
(Fig. 5). Moreover, Vpu S52/56A could partially enhance virion
release (Fig. 2A, 2B) and still retained nearly half the capability of
the wild-type Vpu to mediate tetherin cell surface downregulation
(Fig. 4C) and degradation (Fig. 4A). However, as these
experiments were not based on the virus infection level, we could
still only presume that the b-TrCP pathway is merely involved in
but does not fully account for the antagonism of tetherin by Vpu.
More importantly, a recent report pointed out that b-TrCP is
dispensable for the ability of Vpu to overcome the CD317/
tetherin-imposed restriction on HIV-1 release [46], raising the
possibility that the counteracting mechanism may involve
unknown cellular factors other than b-TrCP. However, the results
of our in vivo binding assay strongly suggested that the binding of
Vpu with tetherin through the TM domain is fundamentally
required for any of their complex biological interactions.
Vpu contributes to the viral effort to downregulate CD4 from
the cell surface and further induce proteasomal degradation of the
protein from the ER [28]. This function of Vpu begins with the
recognition of the cytoplasmic tail of CD4 and recruitment of b-
TrCP [47]. That Vpu S52/56A was found to be impaired in its
ability to induce CD4 degradation (Fig. 6A) and surface
downregulation (Fig. 6C) supported the notion that a b-TrCP-
dependent mechanism is directly involved in the Vpu-induced
degradation of CD4 rather than tetherin. A recent report has
indicated that non-specific interactions between the hydrophobic
membrane helices of CD4 and Vpu may stabilize interactions
between these proteins and contribute to Vpu-induced CD4
degradation [48]. Consistent with these findings, the functional
impairment of Vpu TM CD2I but not other TM mutants towards
CD4 (Fig. 6) suggested that Vpu counteractions against both
tetherin and CD4 require the Vpu TM domain, although the
particular determinants may be located or overlapped at different
regions of the TM domain.
While this manuscript was in preparation, Vigan and Neil [49]
reported that amino acid positions A14, W22 and to a lesser extent
A18 of the Vpu TM domain are required for tetherin antagonism.
We acknowledge that their work presented extensive analysis of
the Vpu TM domain by mutagenesis and illustrated the results by
mapping the determinant amino acids in an NMR structure model
created by PyMol software. They screened the Vpu TM mutants
for rescue of HIV-1 DVpu release in 293T cells with transiently
expressed tetherin and picked three of the most defective mutants
to investigate the mechanism of tetherin antagonism. Although our
observations are largely consistent with their study, the detailed
findings are different. For example, we determined that the
mutants with polarity changes at I15, I16 and I17 which severely
impacted tetherin antagonism, may disturb the formation of an
inside hydrophobic pocket between A14 and A18 located on the
outside-facing side of the tetherin binding surface. Furthermore,
we found that mutations at I26 and I27 displayed not only
moderate effects of Vpu on tetherin antagonism but also a striking
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W22A in the report mentioned above. Therefore, our study
further strengthens the importance of the hydrophobic binding
surface for tetherin antagonism which lies in the core of the Vpu
TM domain. However, due to the continuity and repeatability of
hydrophobic amino acids in the transmembrane helix, studies on
these structures with the traditional analytical method of alanine
scanning may be, at least occasionally, misleading since these
membrane proteins usually do not function like enzymes or soluble
adaptor proteins whose key amino acids with specific character-
istics contribute greatly to their biological function. Our
observation that the Vpu TM M3IV mutant could still efficiently
antagonize tetherin, suggests that substitution of the region in the
binding surface only with amino acids that possess similar polarity
can maintain the structural integrity of the tetherin binding surface
in the transmembrane helix. Meanwhile, these observations also
raised the possibility that Vpu mutants with substitutions at certain
amino acid positions with hydrophobic alanine may give false
negative findings since they may simply mimic the structure which
is potentially important for tetherin interaction. A recent report
also used a similar mutation method and presented data showing
that TM mutants of Vpu that cannot associate with lipid rafts also
have impaired enhanced virus release function, but whether these
defects are correlated with tetherin counteraction has not been
determined [50]. Moreover, molecular dynamic (MD) simulations
on the individual TM domains within hydrated lipid bilayers has
been performed, and it was determined that the TM domain of
Vpu A18H which results in impaired downregulation of tetherin
and reduced virion release is incapable of interacting with the TM
domain of tetherin [36]. However, obtaining the detailed structure
of the Vpu TM domain in complex with tetherin by NMR or
crystallography structure analysis would be most reliable method
for determining the exact nature of their interaction.
Although we have not defined the exact landscape of the binding
interface between Vpu and tetherin, we provided in this study new
evidence suggesting that the Vpu TM domain directly contributes
to the physical interaction with tetherin and additional insight into
the binding model by identifying amino acids within the Vpu TM
domain important for tetherin antagonism. Several NMR analyses
[51,52,53,54,55] have provided us some structural features of the
VpuTMdomain,andotherstructuralstudieshaveshed lightonthe
structure of Vpu as it relates to its function [56,57]. Indeed, the
wealth of existing structural information has enabled the use of
computational methods to clarify the mechanisms of Vpu function
on an atomic scale [58,59,60,61,62]. However, a high resolution
three-dimensional crystal structure of the whole Vpu protein has
been challenging to obtain, predominantly because of the difficulty
in producing the recombinant protein in a soluble and properly
folded form.
The ultimate goal of these studies is of course to aid in the
design of targeted drug therapy. The cholesterol-binding com-
pound amphotericin B methyl ester (AME) was shown to inhibit
virus release in a Vpu-dependent manner, suggesting that it may
disrupt the activity of Vpu to antagonize tetherin, although the
precise target site is unknown [63]. An alternative approach to
disrupting Vpu function is possibly to target the Vpu-tetherin
interface with small molecules or a transmembrane peptide decoy
that binds the Vpu membrane-spanning domain and blocks its
interactions with tetherin [64,65]. While these inhibitors would
have to interfere with a protein-protein interface, the fact that
specific mutations in Vpu can block the binding of the two proteins
is quite encouraging. More detailed structural analysis will be
required to determine the precise mechanism of Vpu protein
counteraction against tetherin during HIV-1 replication.
Materials and Methods
Plasmid construction
The human tetherin gene (Swiss-Prot entries Q10589) was
obtained by PCR amplification from cDNA of HeLa cells and
subsequently subcloned using standard molecular biology proce-
dures into the VR1012 vector for eukaryotic expression with an
HA tag added in frame at its N-terminus. The VR1012 expression
plasmid encoding the codon-optimized HIV-1 NL4-3 Vpu with a
cmyc tag was derived from pcDNA-Vphu [66] with primers that
added a myc tag in frame at its C-terminal end. All of the Vpu
mutants were engineered based on this Vpu-cmyc VR1012 clone
using the QuickChange mutagenesis system (Stratagene), and
sequence confirmed. The human CD4 gene (Swiss-Prot entries
P01730) was obtained by PCR amplification from cDNA of H9
cells and subcloned into the VR1012 vector for eukaryotic
expression with an HA tag added at its C-terminus. The HIV-1
wild-type proviral clone pNL4-3 was obtained from the National
Institutes of Health AIDS Research and Reference Reagent
Program (NIH-ARRRP), and the HIV-1 Vpu-defective version of
the plasmid, pNL4-3 DVpu, was previously described [67].
Cells and transfections
HeLa (ATCC; No. CCL-2) and HEK293T (ATCC; No. CRL-
11268) cells were purchased from the American Tissue Culture
Collection (ATCC), and the MAGI-CCR5 (Catalog No. 3522),-
HeLa CD4 (Catalog No. 459) was obtained from NIH-ARRRP.
All cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) at
37uC/5% CO2. Transfections of HeLa and 293T cells were
performed using Lipofectamine 2000 (Invitrogen), according to
the manufacturer’s instructions. The MAGI-CCR5 cell line, a
HeLa-CD4 cell derivative that expresses CCR5 and that has an
integrated copy of the HIV-1 long terminal repeat (LTR)-driven
b-D-galactosidase reporter gene, was used to analyze the relative
release of the infectious HIV-1 virions.
Immunofluorescence microscopy
Evaluation of cell-associated Vpu protein by immunofluores-
cence microscopy was performed as follows: HeLa cells (20–50%
confluent) seeded on coverslips in a 24-well plate were transfected
with 200 ng of plasmid DNA using Lipofectamine 2000. At 24 h
post-transfection, cells were fixed with 2% formaldehyde in PBS
for 10 min at room temperature. After fixation, cells were
permeabilized with 0.25% Triton X-100 (SIGMA), blocked in
10% FBS in PBS for 20 min and then incubated with a mixture of
mouse monoclonal anti-myc antibody (Millipore) and rabbit anti-
TGN46 antibody (SIGMA) diluted 1:1000 in PBS containing 1%
FBS for 1 h at room temperature. Cells were washed three times
in PBS and stained with a mixture of Alexa Fluor 488 conjugated
goat anti-mouse IgG (Molecular Probes, Invitrogen) and Rhoda-
mine Red-X goat anti-rabbit IgG (Molecular Probes, Invitrogen)
diluted 1:1000 in 1% FBS in PBS for 1 h at room temperature.
Stained cells were washed three times in PBS. The coverslips were
mounted on glass slides with mounting medium cotaining DAPI
(Invitrogen). The samples were observed on an Olympus IX71
fluorescence microscope, and photos were taken with a Nikon
CCD camera and associated imaging system.
Flow cytometry analysis
HeLa cells plated in 6-well plates were transfected with
indicated expression plasmids along with an EGFP-expressing
vector pEGFP-N3 (Clontech) as a transfection marker. After 48 h,
the cells were washed twice with PBS and non-specific binding
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tetherin was stained with an anti-BST-2 monoclonal IgG1
antibody (Abnova) followed by Alexa Fluor 633 conjugated goat
anti-mouse IgG (Molecular Probes, Invitrogen) and analyzed on a
MoFlo XDP cell sorter (Beckman Coulter). The data was then
group analyzed with FlowJo 7.6.2 (Tree Star). Samples were gated
on EGFP+ cells, and the surface tetherin levels are shown in
histograms with median values on the top right corner. A similar
assay was used to measure the cell surface CD4 levels in HeLa
CD4 cells, using an anti-CD4 monoclonal antibody (NIH-
ARRRP) as the primary antibody.
Protein analysis
Unless otherwise indicated, the cells were lysed with RIPA
buffer 48 h post-transfection. Cell lysates from transfected cells
were mixed with SDS sample buffer and boiled for 5 min. The
samples were subjected to standard SDS-PAGE and then
transferred to a nitrocellulose membrane for Western blotting.
Overexpressed tetherin was detected with a mouse monoclonal
anti-HA antibody (Covance) against the HA-tag added on its N-
terminus. While the relative individual tetherin bands in the 28–
37 kDa range varied, the predominant band was analyzed by
densitometric scanning. Overexpressed Vpu was detected with a
mouse monoclonal anti-myc antibody (Millipore) against the myc-
tag added on its C-terminus. Viral Vpu was detected with rabbit
polyclonal anti-Vpu serum (NIH-ARRRP). Pr55Gag and p24CA
were detected with a monoclonal anti-HIV capsid (p24) antibody
obtained from HIV-1 p24 hybridoma (NIH-ARRRP) cultured
supernatant. Tubulin was detected with a mouse monoclonal anti-
tubulin antibody (Covance). Alkaline phosphatase conjugated goat
anti-mouse and goat anti-rabbit IgG (Jackson Immunoresearch)
were used as secondary antibodies for Western blotting. For the
native PAGE, cells were lysed with 100 ml co-IP lysis buffer
containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton
X-100 (SIGMA), 1% CHAPS (SIGMA) and a protease inhibitor
cocktail (Roche). The lysates were then mixed with native sample
buffer without SDS. The samples remained unboiled and
separated on a native gel without SDS in a cold room.
Virion production and infectivity assay
HIV-1 particles were produced by transient transfection of
HeLa or 293T cells in a 6-well plate with 1 mg proviral constructs
and indicated amount of other plasmids. Two days later, 2 ml
supernatants of producer cells were harvested, clarified by
centrifugation and passed through a 0.22 mm filter. The viral
particles were pelleted through a 20% sucrose layer at 110,0006g
for 1 h and resuspended in 30 ml RIPA Buffer. Virus particle
pellets and corresponding cell lysates were analyzed by SDS–
PAGE and Western blot assays using an anti-p24 capsid antibody.
In single-cycle infectivity assays, 100 ml of the filtered supernatant
were mixed with DEAE-dextran (SIGMA) at a final concentration
of 15 mg/ml and incubated with MAGI-CCR5 indicator cells for
1 h, followed by addition of 500 ml fresh medium. At 48 h after
infection, the infected cells were fixed, stained for b-galactosidase
activity and analyzed by counting the blue dots representing
released virion yield.
Co-immunoprecipitation
Transfected 293T cells were lysed on ice for 30 min in 500 ml
lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl,
1% Triton X-100 (SIGMA), 1% CHAPS (SIGMA) and a protease
inhibitor cocktail (Roche), followed by centrifugation at 10,0006g
for 10 min at 4uC to pellet the cellular debris. The clarified cell
lysates were pre-cleared with 30 ml of a 25% Protein G Agarose
slurry (Roche) rocking at 4uC for 1 h, and then the agarose beads
were removed by centrifugation at 10006g for 5 min at 4uC. The
immunoprecipitations were performed on the pre-cleared super-
natants by adding 1 mg of mouse anti-myc antibody for 1 h at 4uC,
followed by adding 30 ml of the 25% Protein G agarose slurry and
incubating for 2 h at 4uC. The beads were centrifuged at 10006g
for 5 min at 4uC and washed with 500 ml lysis buffer. The
centrifugation and wash steps were repeated three times. The
supernatant was removed after the final centrifugation, and the
pellet was resuspended in 30 ml glycine HCl pH 2.0 elution buffer.
The eluates were mixed with SDS-PAGE loading buffer, separated
by SDS-PAGE and analyzed by immunoblotting. After being
transferred onto nitrocellulose membrane, HA-tetherin and Vpu-
cmyc were detected in the Western blots using anti-HA (1:2000
dilution) and anti-myc (1:2000 dilution) antibodies, respectively.
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